ClinicalTrials.gov
public full text
Public Domain
Efficacy of Tocilizumab for the Treatment of Acute AION Related to GCA
AION is the main cause of blindness in patients with GCA. High dose steroid is the reference treatment of this condition, but medical unmet need remains. Subcutaneous tocilizumab, a targeted biotherapy, recently received marketing authorization for the treatment of GCA, but only demonstrated at yet that it can allow steroid dose sparing. The aim of this study is to assess the benefit of tocilizumab and IV steroids combination or IV steroids alone, in the treatment of AION due to GCA.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Safety and Efficacy of Drug Combinations Against Trichuris Trichiura#1437820
- Iparomlimab and Tuvonralimab Combined With GC in Advanced ICC#1074298
- Safety, Tolerability, Efficacy of EA0010 in OTOF Patients With CI#1214354
- Lipid Profile of Tenon's Capsule#896147
- DICLOFENACUM 30mg/g SPUMA CUTANATA#139594
Record · ID 1445488
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive